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Abstract. Acquired behavioral changes have essentially been described in advanced multiple sclerosis (MS). The present study
was designed to determine whether behavioral modifications specifically related to the MS pathological process could be identified
in the initial phase of the disease, as compared to control patients with chronic, relapsing and progressive inflammatory disorders
not involving the central nervous system (CNS). Eighty-eight early MS patients (Expanded Disability Status Scale score  2.5)
and 48 controls were tested. Perceived changes by informants in behavioral control, goal-directed behavior, decision making,
emotional expression, insight and interpersonal relationships were assessed using the Iowa Scale of Personality Change (ISPC).
Executive behavioral disturbances were screened using the Dysexecutive Questionnaire (DEX). The mean change between the
premorbid and postmorbid ISPC ratings was similar in the MS [12.2 (SD 15.6)] and in the control [11.5 (SD 15.1)] group. The
perceived behavioral changes (PBCs) most frequently reported in both groups were lack of stamina, lability/moodiness, anxiety,
vulnerability to stress and irritability. Pathological scores in the DEX were also similar in both groups. Correlations between
PBCs and DEX scores were different in MS and control groups. MS patients with cognitive impairment had a marginally higher
number of PBCs than control patients (p = 0.056) and a significantly higher DEXp score (p = 0.04). These results suggest that
(1) PBCs occurring in early MS patients were not different from those induced by comparable chronic non-CNS disorders, (2)
qualitative differences in the relationship between behavioral symptoms and executive-behavioral changes may exist between MS
and control groups, and (3) behavioral symptoms seem associated with cognitive deficits in MS. We further plan to assess these
observations longitudinally.
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1. Introduction
Cognitive dysfunction has been well documented in
multiple sclerosis (MS) and occurs in up to 60% of MS
patients [14,18]. However, the behavioral and affective
impairments linked to MS have not been systematically
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investigated, especially in early MS, and are generally
not part of the health status assessment of MS patients.
Behavioral manifestations, classically described as a
variety of mood-related symptoms, such as cheerful-
ness, optimism, denial of disability, and pathological
laughing, were once considered the hallmark of MS
but are, in fact, rather rare [19]. Such behavioral al-
terations are thought to represent more an associated
feature of MS induced central nervous system (CNS)
pathology, rather than a maladaptive response of the
subjects and are, consequently, prone to remain stable.
In particular, euphoric mood aberrations seem to be
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substrate-dependent disturbances and tend to evolve in
parallel with disease duration and severity [7]. Other
behavioral changes, such as agitation, irritability, apa-
thy and disinhibition, are frequent [6] and seem to play
an important role in MS [5]. It is therefore reasonable
to hypothesize that behavioral changes are present ear-
ly in MS and may not necessarily be linked to purely
cognitive or adaptative parameters.
While the above studies suggest that, in advanced
MS, behavioral changes are consistent with the ac-
quired neurological dysfunction, this is still debatable
in the initial phase of the disease. In the early phase,
such modifications may be due to two different mech-
anisms: (i) alterations of cortical and subcortical cir-
cuits involving the orbitofrontal, medial and dorsolat-
eral prefrontal cortex [21], which modify patients’ be-
havior [12] or their ability to verbalize the emotional
status [16], or (ii) maladapted coping responses, which
may occur during any chronic illness (also non neu-
rological) characterized by an unpredictable function-
al decline, that may have clinically relevant psycho-
logical implications [1,8]: a chronic disease such as
MS, may represent a challenge to face, and patients’
affective reactions, depending on their personality and
cognition, could then play a role in their adaptative (or
maladaptive) behavior. Distinguishing between these
two mechanisms is important, as it may influence the
type of therapeutic approach that is indicated.
This study was designed to evaluate behavioral
changes in a homogeneous cohort of early MS pa-
tients with minor impairment in parallel to a compara-
ble cohort of control patients with chronic, relapsing,
and progressive disorders not involving the CNS. Be-
havioral modifications occurring in neurological dis-
eases have recently been approached by the mean of
scales which measure changes perceived by patients’
informant [2], and initially employed for the assess-
ment of traumatic brain injury patients. These scales
represent an advance in the quantitative measurement
of specific behavioral and behavioral-executive symp-
toms and have been used in different neurological con-
ditions. We hypothesized that such changes occur in
early MS and questioned whether they are MS-specific.
Changes specific to MS would be a sign that behav-
ioral changes early in the course of the disease could be
due to preclinical subcortical dysfunction, whereas the
occurrence of identical behavioral changes both in dis-
eased controls and MS patients would argue that early
behavioral modifications are related to a non-specific
psychological reaction to sickness.
2. Materials and methods
2.1. MS and control patients
Eighty-eight patients with a diagnosis of MS or pos-
sible MS based on McDonald criteria [15,17] were test-
ed. Of these, 51 had relapsing-remitting (RR) MS, an-
other 13 with confirmed MS had experienced a single
relapse and showed dissemination in time and space
proven by magnetic resonance imaging (MRI), and 24
patients had possible MS with a single relapse, posi-
tive oligoclonal bands in the cerebrospinal fluid, and
a positive MRI at the time of diagnosis. Ten of these
24 patients developed a second relapse during follow-
up, confirming the diagnosis of MS (mean interval to
diagnosis confirmation: 11.7 months, SD 8.8).
The criteria used to define our early MS popula-
tion were: (i) an Expanded Disability Status Scale
(EDSS) [13] score  2.5, (ii) no or little handicap for
vocational and leisure activities measured on the Lon-
don Handicap Scale [11], then transposed to a validat-
ed functional score ranging from 1 to 4 according to
the classification used in the global functional status in
rheumatoid arthritis (see Table 1) [9], (iii) MS duration
>3 months and  5 years. Medication, in particular
interferon-β1a or 1b and antidepressants, was not con-
sidered an exclusion criterion. All MS patients were
evaluated for long-term memory (Rey’s Auditory Ver-
bal Learning Test), executive functions (Behavioural
Assessment of the Dysexecutive Syndrome) and atten-
tion (Trail Making Test) [12]. Cognitive impairment
was defined by a performance two standard deviations
(SD) below the appropriate mean for a given test. Fa-
tigue was assessed using the severity subscore of the
Fatigue Assessment Instrument (FAI) [20] (cut-off val-
ue < 4.89).
Forty-eight control patients without CNS involve-
ment and comparable in terms of age, education, and
handicap were recruited. These patients suffered from
systemic inflammatory disorders that, like MS, evolve
chronically with exacerbations: rheumatoid arthritis
(n = 11), ankylosing spondylarthritis (n = 13), pso-
riatic arthritis (n = 1), motor multifocal neuropathy
(n = 2), and inflammatory bowel disease (n = 21). All
participating control patients had no or only a minor
handicap for vocational and leisure activities according
to the classification of functional status in rheumatoid
arthritis [9], and a disease duration of >3 months and
 10 years (a higher upper limit than that used for the
MS patients was chosen to obtain a large enough num-
ber of controls because of the longer time needed to
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Table 1
Demographic data for the MS and control patients
MS patients (n = 74) Control patients (n = 48)
Female gender [n (%)] 50 (67.6) 24 (50)
Age (years) [mean (SD)] 34.1 (9.9) 31.5 (8.9)
< 9 years (%) 13.5 25.0
Schooling 9–12 years (%) 59.5 45.8
> 12 years (%) 27.0 29.2
Disease duration (years) [mean (SD)] 2.5 (1.7) 5.0 (3.0)
Handicapa [mean (SD)] 1.7 (0.4) 1.9 (0.7)
(class 1: n = 36; class 2: (class 1: n = 14; class 2:
n = 23; class 3: n = 15) n = 27; class 3: n = 7)
Immunomodulatory therapy [n (%)] 32 (46.4) 20 (45.5)
Antidepressants [n (%)] 5 (6.7) 2 (4.2)
aHandicap rated according to the functional scale used in rheumatoid arthritis [9] as: class 1 =
able to perform usual activities of daily living (self-care, vocational, and avocational); class 2 =
able to perform usual self-care and vocational activities, but limited in avocational activities; class
3 = able to perform usual self-care activities, but limited in vocational and avocational activities;
class 4 = limited in ability to perform usual self-care, vocational, and avocational activities.
develop an equivalent handicap in these disorders). Im-
munomodulatory, immunosuppressive and antidepres-
sive treatments were permitted. Since they were young
adults with no CNS pathology, the controls were not
assessed for cognition.
MS and control patients presenting psychiatric disor-
ders diagnosed according to the DSM-IV criteria were
not excluded. Inclusions were performed at distance
from exacerbations or corticosteroid treatment ( 6
weeks). All patients signed an informed consent form
before participating in this study, which had been ap-
proved by the local Ethical Committee.
2.2. Scales measuring behavioral changes
The Iowa Scale of Personality Change (ISPC) [2]
provides, through 26 behavioral symptoms related to
maladaptive functioning, an exhaustive checklist of the
modifications that can occur after brain lesions in the
affective, behavioral and social dimensions, and mea-
sures the extent of the change that an informant per-
ceives in the patients’ behavior in comparison to his/her
premorbid status (Fig. 1). This scale has been validated
for patients’ informants in a wide range of neurological
disorders, and was chosen as a useful tool in previous
studies focused on perceived behavioral changes in dif-
ferent neurological conditions [3,10]. The information
is provided by a close relative who was familiar with
the patient before the onset of the disease. Two global
scores are obtained from the sum of the ratings for all
items, the first reflecting the patient’s perceived behav-
ior during the six months period before disease onset
(premorbid score) and the second corresponding to the
patient’s perceived behavior at inclusion in the study
(postmorbid score) [3]. The difference between these
two scores provides a measure of the perceived extent
of the changes (differential score). The ISPC includes
also three characteristics (vanity, frugality and manip-
ulativeness), not found in acquired brain damage and
examined to detect possible response biases. A change
of>3 in any of these three “control” items invalided the
patient’s rating. A second measurement was to detect
which behavioral symptom was significantly increased
or decreased (defined by Barrash [3] as acquired per-
sonality traits [APTs], but that we will rename here
perceived behavioral changes [PBCs]). PBCs were
defined, for each patient, as scores showing at least a
moderate disturbance in the postmorbid state (cut-off
score 4) with a change in score of  1 from the pre-
morbid level. The 26 subscales can be grouped into the
five main factors of distress, impaired ego functioning,
executive dysfunction, interpersonal disturbance, and
hypo-emotionality. These factors were also used for
analysis.
The Dysexecutive Questionnaire (DEX) [24], one
of the few available standardized rating scales, was
used for quantifying behavioral disturbances common-
ly associated with executive impairment. The 20 items
of the DEX encompass broad areas of likely changes,
which can be grouped into the five factors of inhibition,
intentionality, executive memory, positive affect, and
negative affect [4]. Each item is scored on a 5-point
scale ranging from “never” to “very often” (0 to 4).
Unlike the ISPC, the DEX is provided in two versions,
DEXp (cut-off value <38), designed to be complet-
ed by the patient, and DEXr (cut-off value <24.5), to
be completed by a close relative; both were used for
analysis.
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Fig. 1. Example of a rating sheet for one item of the ISPC (total number of items: 29). For each item, a rating of 1 indicates excellent, 3 average,
4–5 moderate disturbance, and 6–7 severe disability. Ratings 1, 3, 5, and 7 correspond to brief definitions of the worsening of the different
behavioral characteristics, while ratings 2, 4, and 6 reflect intermediate measurements.
2.3. Statistical analysis
We calculated for the three main outcomes and for
the actual sample sizes the difference that could be
evidenced with a power of 80%. MS patients should
have had a mean number of PBCs of 7.1 (SD 5) for a
difference could be shown with control patients (mean
4.4, SD 5). For the DEXr score, the test could show
a difference between 20.0 and 26.3 (SD = 12) and for
the DEXp score, between 23.9 and 30.2 (SD = 12). A
Wilcoxon test was used to compare demographical da-
ta, handicap, DEX and ISPC scores between the control
and MS groups and for subgroup analysis. To address
difference between paired measures of ISPC scores (be-
fore onset and at inclusion) and of DEX scores (DEXp
and DEXr), a paired Wilcoxon test was performed. For
the refined analysis of ISPC items, the percentage of
patients by group meeting the PBC criteria was cal-
culated for each item. An exploratory analysis was
conducted to screen items with a large difference be-
tween both groups using independent chi2 tests. Cor-
relations between the DEX and ISPC scores were ex-
amined using the Spearman correlation. DEX scores
and the number of PBCs were fitted by a MANOVA
model including gender, grouping of patients (controls,
MS patients without cognitive deficits and with cog-
nitive deficits), and an interaction term. The level for
statistical significance was taken as a p-value<0.05.
3. Results
Seventy-four of the 88 MS patients tested were re-
tained for analysis, since 14 patients with possible MS
did not confirm their diagnosis during the follow-up pe-
riod determined by the time necessary to complete this
study. The demographic data for the MS and control
patients are summarized in Table 1. The two groups
were comparable in terms of age (p = 0.1), education
(p = 0.1), handicap (p = 0.1), and immunomodula-
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Table 2
Values for, and difference between, the global ISPC scores in the MS and control patients
MS patients (n = 69) Control patients (n = 44) p value
Mean (SD) Mean (SD)
Premorbid ISPC 67.3 (14.7) 64.0 (10.7) 0.3
Postmorbid ISPC 79.5 (17.8) 75.4 (18.0) 0.2
Difference 12.2 (15.6) 11.5 (15.1) 0.7
pvalue < 0.001 < 0.001
tory therapy (p = 0.9). Marginal gender effect (p =
0.05) reflects the female overrepresentation classical-
ly observed in MS population. Twenty-five MS pa-
tients (33.8%) had cognitive deficits. Executive impair-
ment, known to be associated with certain behavioral
changes, was seen in five patients. Pathological fatigue
symptoms were reported by 54.4% of the MS patients.
Finally, 4 MS patients had a diagnosis of depression
according to the DSM-IV criteria and 5 were receiving
antidepressants.
3.1. ISPC scores in the MS and control groups
Five MS patients and 4 controls were excluded from
the analysis because of missing values or of a differen-
tial score of >3 for one of the “control” items. The av-
erage global ISPC score, thus based on 69 MS patients
and 44 controls, was in the MS group 67.3 (SD 14.7)
before MS onset and 79.5 (SD 17.8) at inclusion, the
respective corresponding values for the control group
being 64.0 (SD 10.7) and 75.4 (SD 18.0) (Table 2). The
two groups were similar in terms of premorbid score
(p = 0.3) and postmorbid score (p = 0.2). The mean
difference between the premorbid and postmorbid rat-
ings was 12.2 (SD 15.6) in the MS group and 11.5 (SD
15.1) in the control group. There was no difference be-
tween the groups in terms of the extent of the changes
(p = 0.7) but postmorbid scores were indeed statisti-
cally different from premorbid scores in both groups
(p < 0.001 in both groups).
3.2. Frequency of PBCs in MS and control patients:
item by item analysis
The MS and control groups were compared by evalu-
ating the number of items satisfying the conditions for a
PBC (postmorbid score 4, difference 1). The aver-
age number of PBCs was 4.8 (SD 5.2) in the MS group
and 4.4 (SD 5.0) in the control group. The Wilcoxon
test showed no difference between the groups in the
distribution of the number of PBCs (p = 0.7). The per-
centage of patients in both groups meeting the PBC cri-
teria for each item is shown in Table 3. Five items were
considered as PBCs in more than 30% of MS patients;
all five also met the PBC criteria in more than 25% of
the controls. More than 50% of MS patients were per-
ceived by their relatives as having changed on the item
lack of stamina, 40% on the item lability/moodiness,
and more than 30% were perceived as more irritable,
anxious, and vulnerable to stress. Ranking the items
according to the frequency of patients being perceived
by their relative as having changed issued in a quite
similar order in both groups (Spearman’s rho = 0.72).
The item inflexibility, present in 26.1% of MS patients
vs. 9.1% of controls (p = 0.02) showed discrepan-
cy. The item lack of stamina was significantly higher
(p = 0.002) in MS patients with a significant fatigue
score (70.2%) than in those with a low score of fatigue
(34.2%).
3.3. Subgroup analysis of the number of PBCs
A subgroup analysis was done on the basis of gender,
disease duration, immunomodulatory treatment, and
cognitive status (this last factor concerning only MS
group). The average number of PBCs was higher in
women (6.2, SD 5.4) than in men (2.6, SD 3.9) in the
control group (p = 0.01), but not in the MS group (4.9,
SD 5.5 vs. 4.6, SD 4.4, respectively; p = 0.9). A
subgroup analysis for gender showed no difference in
the number of PBCs between controls and MS patients
(p = 0.1 for both gender). Comparing the number of
perceived behavioral changes between patients divided
into subgroups according to disease duration (< 2.5
years vs. > 2.5 years), no significant difference was
shown either in the controls (mean 6.0,SD 3.9 vs. mean
4.0, SD 5.2; p = 0.06) or the MS group (mean 5.5, SD
5.8 vs. mean 3.9, SD 4.1; p = 0.4). Immunomodulatory
therapy was not associated to an increased number of
PBCs in the treated (mean 3.9, SD 5.3) vs. non-treated
(mean 4.8, SD 4.8) control subgroups (p = 0.4). In the
MS patients, the number of PBCs was 5.8 (SD 4.8) in
the treated and 4.0 (SD 5.4) in the non-treated subgroup
(p = 0.06).
Concerning cognition, the intragroup analysis re-
vealed that the mean number of PBCs differed signifi-
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Table 3
Percentage of MS and control patients showing a PBC for each of the 26
items of the ISPC
ISPC scale MS patients (%) Control patients (%)
Lack of stamina 52.2 43.2
Lability/moodiness 40.6 34.1
Irritability 33.3 31.8
Anxiety 31.9 40.9
Vulnerability to stress 31.9 27.3
Depression 27.5 25.0
Inflexibility 26.1 9.1
Impatience 21.7 27.3
Social withdrawal 21.7 9.1
Apathy 18.8 11.4
Obsessiveness 15.5 11.4
Indecisiveness 15.9 13.6
Dependency 15.9 18.2
Insensitivity 14.5 13.6
Lack of initiative 14.5 18.2
Suspiciousness 13.0 15.9
Impulsivity 11.6 9.1
Lack of persistence 10.1 11.4
Lack of insight 10.1 4.6
Perseveration 10.1 13.6
Type A behavior 10.0 11.9
Blunted emotional experience 8.7 13.6
Lack of planning 8.7 20.5
Aggression 8.7 2.3
Poor judgment 8.7 6.8
Inappropriate affect/emotion 7.2 4.6
Social inappropriateness 2.9 4.6
Table 4
Values for, and difference between, the two DEX total scores
MS patients (n = 73) Control patients (n = 47) p value
Mean (SD) Mean (SD)
DEXp 24.6 (11.7) 23.9 (12.4) 0.7
DEXr 20.9 (13.7) 20.0 (11.4) 0.9
Difference 3.7 (9.8) 3.9 (8.6) 0.9
p value 0.003 0.008
cantly (p = 0.005) between MS patients with cognitive
deficits (mean 7.7, SD 6.8) and those without (mean
3.4, SD 3.5). A subsequent analysis showed that the
25 cognitively impaired MS patients had a marginal-
ly higher number of PBCs than control patients (p =
0.056).
3.4. DEX global scores
One MS patient and one control were excluded from
the analysis because of missing values. Using the
DEXr [24], 35.6% of MS patients and 25.5% of con-
trols had a significant pathological score although both
groups did not differ significantly (p = 0.2). The scores
for DEXp, DEXr and the difference between the two
(DEXp-DEXr) were comparable in both groups (Ta-
ble 4). Relatives’ ratings were significantly lower than
patients’ ratings in both groups (MS group: p = 0.003;
control group: p = 0.008). The Spearman correlations
of DEXp and DEXr were 0.59 (95% CI: 0.40,0.73)
in the MS group and 0.65 (95%CI: 0.43,0.80) in the
control group.
3.5. DEXr subgroup analysis
Subgroup analysis for gender showed that DEXr
score was significantly higher for women (mean 24.6,
SD 11.6) than for men (mean 15.9, SD 9.5) in the con-
trol group (p = 0.005). In the MS group, DEXr was
lower for women (mean 18.6, SD 11.7) than for men
(mean 25.9, SD 16.6) but the difference was not sig-
nificant (p = 0.08). A significant difference between
MS and control patients was shown for men (p = 0.03)
and women (p = 0.04). No association was found be-
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Table 5
Spearman correlations between selected corresponding ISPC (postmorbid scores) and DEXr items
ISPC items DEX items MS 95%CI Control 95%CI
Impulsivity Item 2 0.39 0.16,0.58 0.68 0.47,0.82
Lack planning Item 4 0.23 −0.1,0.45 0.32 0.02,0.57
Irritability Item 5 0.56 0.37,0.71 0.46 0.18,0.67
Item 12 0.47 0.26,0.64 0.48 0.20,0.69
Lack insight Item 7 0.23 −0.01,0.45 0.16 −0.15,0.44
Apathy Item 8 0.44 0.22,0.62 0.41 0.12,0.64
Social inappropriateness Item 9 0.27 0.03,0.48 0.40 0.11,0.63
Item 20 0.35 0.12,0.55 −0.12 −0.41,0.19
Item 13 0.49 0.28,0.66 0.33 0.03,0.58
Blunted emotional experience Item 11 0.27 0.03,0.48 −0.05 −0.35,0.26
Perseveration Item 14 −0.11 −0.34,0.14 0.05 −0.26,0.35
Item 16 0.01 −0.23,0.25 0.22 −0.09,0.49
Lack of persistance Item 18 0.43 0.21,0.61 0.30 −0.01,0.56
tween DEXr scores and disease duration (cut-off 2.5
years) either in MS (mean 20.0, SD 11.4 vs. mean 17.9
SD 10.8; p = 0.2) or for controls (mean 21.4, SD 6.7
vs. mean 19.8 SD, 12.4; p = 0.9). Patients receiv-
ing immunomodulatory or immunosuppressive treat-
ments were also similar to untreated patients in MS
patients (p = 0.3) and in control diseases (p = 0.7).
DEXr scores did not differ between MS patients with
and without cognitive impairment (mean 19.1, SD 12.7
vs. mean 24.6, SD 15.3; p = 0.1). MS patients with
cognitive deficits had DEXr scores similar to control
patients (p = 0.2).
3.6. DEXp subgroup analysis
Subgroup analysis for gender showed that DEXp
score was marginally higher for women (mean 27.1,
SD 13.7) than for men (mean 20.1, SD 9.8) in the
control group (p = 0.056). In the MS group, there
was no gender effect (women: mean 23.8, SD 11.2;
men: mean 26.2, SD 12.8; p = 0.4). Finally, DEXp
score was not significantly different between MS and
control patients, neither for women nor for men. No
association was found between DEXp scores and the
duration of the disease for both groups (MS patients:
mean 25.9, SD 10.9 vs. mean 20.9, SD 9.9; p = 0.2;
controls: mean 22.7, SD 10.1 vs. mean 23.9, SD 13.5;
p = 0.7). Patients receiving immunomodulatory or im-
munosuppressive treatments had similar DEXp scores
that untreated MS (mean 23.8, SD 10.6 vs. mean 25.2,
SD 12.7; p = 0.7) and control patients (mean 23.0, SD
9.8 vs. mean 24.2, SD 12.6; p = 0.9).
Concerning cognition, the intragroup analysis
showed that DEXp score was higher in MS patients
with cognitive impairment (mean 29.2, SD 10.7) than
in those without (mean 22.3, SD 11.6; p = 0.009).
A subsequent analysis revealed that MS patients with
cognitive deficits had DEXp scores significantly higher
than control patients (p = 0.04).
3.7. Correlations between DEX and ISPC scores
A 78% higher correlation was found between the
number of PBCs and the DEXr score for the MS
group (Spearman’s rho = 0.66 (95%CI: 0.50,0.78);
p < 0.001) than for controls (Spearman’s rho = 0.37
(95%CI: 0.07,0.61); p = 0.01). A correlation was
found between the number of PBCs and the DEXp score
for the MS group (Spearman’s rho = 0.45 (95%CI:
0.23,0.62); p <0.001) but not for the control group
(Spearman’s rho = 0.27 (95%CI: −0.04,0.53); p =
0.07). Here, the strength of correlation was 66% higher
in the MS group than for controls.
Spearman correlation between ISPC dysexecutive
factor (postmorbid score) and DEXr total score was
0.52 (95%CI: 0.32,0.68) in the MS group, and 0.36
(95%CI: 0.06,0.60) in the control group, whereas for
the DEXp total score it was 0.39 (95%CI: 0.16,0.58)
in the MS group and 0.25 (95%CI: −0.06,0.52) in the
control group. Correlations between items aimed to
measure the same behavioral symptoms in the ISPC
and the DEXr scale were satisfying for irritability, ap-
athy, social inappropriateness and lack of persistance
in both groups (Table 5).
Finally DEXp and DEXr scores, and the number of
PBCs were jointly fitted using a multiple analysis of
variance with gender, grouping of patients (controls,
MS patients without cognitive deficits and with cog-
nitive deficits), and an interaction term for gender and
the 3 groups. Adjusted estimated means and 95% con-
fidence interval are shown in Table 6. The interaction
term was significant (p = 0.001).
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Table 6
Estimated mean of DEX scores and the number of PBCs with 95% confidence intervals adjusted for MS (with
[ci−] and without [ci+] cognitive impairment) and control groups and gender
Men Women
Patients MS [ci+] MS [ci−] Control MS [ci+] MS [ci−] Control
DEXp 31.0 20.2 19.2 25.6 22.7 27.8
(22.6,39.4) (14.1,26.4) (14.3,24.1) (19.7,31.5) (18.9,26.5) (23.0,32.6)
DEXr 28.3 17.4 13.9 17.2 18.6 25.7
(20.4,36.2) (11.6,23.2) (9.3,18.5) (11.6,22.8) (15.1,22.2) (21.2, 30.2)
Number of PBCs 7.4 2.7 2.8 7.9 3.6 6.2
(3.8,11.0) (0.0,5.3) (0.6,4.9) (5.4,10.5) (2.0,5.3) (4.0, 8.3)
4. Discussion
PBCs were assessed simultaneously in early MS pa-
tients and in a comparable chronic non-CNS inflam-
matory disease group with no more than minimal func-
tional impairment. The main results coming out of our
analyses were the followings: i) global DEX scores
showed that patients did not underestimate their behav-
ioral modifications compared to informants, thus argu-
ing against anosognosia in the early phase of MS, such
as in the control group; ii) informants perceived similar
behavioral changes in both MS and control groups, ar-
guing against a pattern of behavioral changes specific
for early MS; iii) however, differences were observed
in the relationship between the number of PBCs and
DEX scores in MS and control patients; moreover, the
subgroup of cognitively impaired MS patients tended
to have more behavioral changes than controls.
The DEX scores provided by the patients and their
relatives were slightly but significantly higher in pa-
tients in both groups, suggesting that patients tended
to over-evaluate their behavioral changes compared to
their relatives in the perception of the executive behav-
iors. This pattern is unusual in neurological patholo-
gies, where patients after focal lesions or diffuse lesions
tend to underestimate their difficulties [23]. A limita-
tion could be the cross-sectional design of this study
and such data should be confronted with a longitudi-
nal follow-up. However, the present results may give
indices for the interest of this type of research early in
the MS process, while patients are still active and fully
ambulatory. These data confirm other studies [5] which
demonstrated that behavioral modifications such as ap-
athy, desinhibition and dysexecutive syndrome were
perceived more intensely by the patients than the rel-
atives, and argue against the presence of anosognosia
in early MS. This is further supported by the direct
comparison between DEXp and DEXr reports showing
a good consistency of DEX scores obtained from pa-
tients and relatives, as well as by the minor modification
obtained for the item lack of insight in the ISPC.
The results obtained through the ISPC also evidenced
the occurrence of perceived behavioral modifications
in early MS. Irritability, lack of stamina, anxiety, labil-
ity/moodiness, and vulnerability to stress were behav-
ioral symptoms perceived as changed in more than 30%
of MS patients. This result is partly due to the fact that,
to improve sensitivity, we used a cut-off value (ISPC
score4) one point lower than that used in the original
methodology [3]. The use of a unique questionnaire
to the informant that does not include presently a com-
plementary version intended to be completed by the
patient him/herself prevents controlling for a possible
exaggeration or underscoring of the PBCs. Howev-
er, this possibility is unlikely since the differences we
obtained between the DEXr and DEXp scores suggest
that early MS patients tend to over-score their behav-
ioral changes. An important result was that the control
group had a virtually identical frequency of PBCs than
MS patients. The similar profile of changes found in
other chronic inflammatory diseases not affecting the
CNS questions whether these findings are related to
early MS pathology.
On the other hand, some of our results suggest that
qualitative behavioral differences exist between MS
and control patients. First, the relationship between the
number of PBCs and DEX scores was markedly dif-
ferent between MS and control subjects, with a Spear-
man’s rho value in the former group 78% larger than
in the controls for the DEXr, and 66% larger for the
DEXp. Thus, patients’ executive behaviors and infor-
mants’ PBCs look to be differently related in the two
groups of patients. Illustrations of such differences can
be found in our correlative analysis between DEXr and
ISPC items belonging to the same factors and shown in
Table 5: items such as impulsivity, social inappropriate-
ness, or lack of persistence were characterized by very
different correlative values in MS and control groups,
suggesting that these symptoms may have different con-
sequences in the functioning of these groups. Second,
we showed that cognitively impaired MS patients had
more behavioral changes (ISPC, DEXp). These data
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may indicate that in MS patients, cognitive deficits are
associated in a non-random way to behavioral changes,
although this ought to be developed in a longitudinal
study with the specific question of a relation between
cognitive and behavioral changes [22]. The observa-
tion that MS patients treated with immunomodulators
scored slightly higher on the ISPC than untreated MS
patients gives a additional weight to the interpretation
that a neurological dimension is expressed in the PBCs.
MS patients are indeed more likely to be given chronic
treatment if they are at higher risk of developing severe
MS, as assessed by clinical and laboratory parameters
(e.g. relapse rate, relapse recovery, EDSS changes, and
lesion load and activity on the brain MRI), suggesting
that this “at risk” subgroup of MS patients could show
more affective changes.
In conclusion, this cross-sectional study is in favor of
the presence of similar behavioral modifications both
in MS and in other non CNS chronic disorders, and
gives no strong argument for the detection of an MS-
specific behavioral profile in the early stage of this dis-
ease. However, the qualitative differences in MS and
control patients concerning the relationship between
executive-behavior and PBCs, as well as the associa-
tion observed between cognitive deficits and the occur-
rence of PBCs in the MS group, suggest a neurological
origin and need further investigations to better under-
stand its specificity for MS pathology. These variations
may represent the first signs of a delayed behavioral
change occurring in more advanced MS and related to
a greater extent of the disease. Nevertheless, this study
has some methodological limitations related to missing
informations on the reliability of the scales used, to
the unbalanced size of the two groups of patients who
were not matched for gender (this being related to the
female overrepresentation usually observed in any MS
population), and finally to the bias introduced by any
cross-sectional design evaluating behavioral changes.
For these reasons, the present MS cohort will be eval-
uated longitudinally in the aim to determine which be-
havioral traits develop further during the course of MS,
and are thus specific manifestations of the MS process.
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